

Freedom of Information Request: Our Reference CTHB_393_16

You asked:

For Hepatitis C patients:

How many patients in total are under your care, but not under any treatment (i.e. no drugs being given for this virus)?

If possible please split by Genotype, as set out below:

	Genotype						
	1A	1B	2	3	4	5	6
TOTAL	8	**	**	18	**	0	0

For Hepatitis C patients, how many were treated in the month (last month's available data) with interferon containing therapy and interferon free therapy as listed below. Please use the tables to enter by genotype if possible, thank you.

Total Patients Treated in last month

	Genotype						
TOTAL	1A	1B	2	3	4	5	6
	10	**	**	**	0	0	0

Treatment Regimens in last month by Genotype

	Genotype						
Interferon containing Treatment	1A	1B	2	3	4	5	6
Peg/RBV	0	0	0	0	0	0	0
<u>Victrelis</u> /boceprevir (Peg/RBV)	0	0	0	0	0	0	0
<u>Incivo</u> / telaprevir (Peg/RBV)	0	0	0	0	0	0	0
<u>Olysio</u> /simeprevir (Peg/RBV)	0	0	0	0	0	0	0
<u>Sovaldi</u> / sofosbuvir (Peg/RBV)	0	0	0	0	0	0	0
<u>Daklinza</u> / daclatasvir (Peg/RBV)	0	0	0	0	0	0	0

Interferon Free Treatment	1A	1B	2	3	4	5	6
<u>Harvoni</u> / sofosbuvir + ledipasvir	**	0	0	0	0	0	0
<u>Sovaldi</u> / sofosbuvir	0	0	**	0	0	0	0
<u>Sovaldi/Olysio</u> / sofosbuvir/	0	0	0	0	0	0	0

simeprevir							
<u>Sovaldi/Daklinza</u> / sofosbuvir / daclatasvir	0	0	0	**	0	0	0
<u>Viekirax/</u> ombitasvir/paritaprevir/ritonavir	0	0	0	0	0	0	0
<u>Viekirax/Exviera</u> ombitasvir/paritaprevir/ritonavir + dasabuvir	8	**	0	0	0	0	0

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 1998, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles set out in Schedules 2 and 3 of the Act. Section 40 is an absolute exemption and does not require the Health Board to consider the public interest test.

In respect of Acromegaly patients, please can you tell me:

1. The number of patients with acromegaly under your care, and
2. The number of patients with acromegaly, under your care, being treated with somatostatin analogues.

I can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.